Presentation, pathogenesis, and treatment of migraine

  • Elizabeth W. Loder
Part of the Progress in Inflammation Research book series (PIR)


Migraine is an intermittent headache syndrome whose pattern is generally easily recognized. It is comprised of a combination of signs and symptoms no one of which (other than headache) is absolutely required for diagnosis. Attacks can occur almost daily or very rarely, indicating that the threshold for experiencing an attack may vary from person to person. In an effort to standardize diagnosis, the International Headache Society has devised diagnostic criteria [1]. These have been useful for research purposes but perform less well in the clinical setting. Nonetheless, these criteria are widely accepted and used. They are summarized in Table 1.


Migraine Attack Essential Tremor Naproxen Sodium Migraine Patient Migraine With Aura 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    International Headache Society (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8 (Suppl 7): 1–96Google Scholar
  2. 2.
    Goadsby PJ (2000) Headache. In: DA Warrell, TM Cox, JD Firth (eds): Oxford Textbook of Medicine. Oxford Press, Oxford, 343–349Google Scholar
  3. 3.
    Goadsby PJ, Lambert GA, Lance JW (1982) Differential effects on the internal and external carotid circulation of the monkey evoked by locus coeruleus stimulation. Brain Res 249: 247–254PubMedCrossRefGoogle Scholar
  4. 4.
    Drummond PD, Lance JW (1984) Neurovascular disturbances in headache patients. Clin Exp Neurol 20: 93–99PubMedGoogle Scholar
  5. 5.
    Honkasalo ML, Kaprio J, Winter T et al (1995) Migraine and concomitant symptoms among 8,167 adult twin pairs. Headache 35: 70–78PubMedCrossRefGoogle Scholar
  6. 6.
    Peroutka SJ, Wilhoit T, Jones K (1997) Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) Nco1 alleles. Neurology 49: 201–206PubMedCrossRefGoogle Scholar
  7. 7.
    Ophoff RA, Terwindt GM, Vergouwe MN et al (1996) Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca 2+ channel gene CACNLIA4. Cell 87: 543–552PubMedCrossRefGoogle Scholar
  8. 8.
    Nyholt DR, Lea RA, Goadsby PJ et al (1998) Familial typical migraine: linkage to chro-mosome 19p13 and evidence for genetic heterogeneity. Neurology 50: 1428–1432PubMedCrossRefGoogle Scholar
  9. 9.
    Hans M, Luvisetto S, Williams ME et al (1999) Functional consequences of mutations in the human alpha 1A calcium channel subunit linked to familial hemiplegic migraine. J Neurosci 19: 1610–1619PubMedGoogle Scholar
  10. 10.
    Yakhinista VA, Pilyayskii AI, Limansky YP, Bulgakova NV (1996) Modulation of the activity of midbrain central gray substance neurons by calcium channel antagonists in vitro. Neuroscience 70:159–167CrossRefGoogle Scholar
  11. 11.
    Ramadan NM, Halvorson H, Vande-Linde A et al (1989) Low brain magnesium in migraine. Headache 29: 416–419PubMedCrossRefGoogle Scholar
  12. 12.
    Aurora SK, Cao Y, Bowyer SM, Welch KMA (1999) The occipital cortex is hyperexcitable in migraine experimental evidence. Headache 39: 469–476PubMedCrossRefGoogle Scholar
  13. 13.
    Wray SH, Mijovic-Prelec D, Kosslyn SM (1995) Visual processing in migraineurs. Brain 118: 25–35PubMedCrossRefGoogle Scholar
  14. 14.
    Wang W, Schoenen J (1998) Interictal potentiation of passive “oddball” auditory event-related potentials in migraine. Cephalalgia 18: 261–265PubMedCrossRefGoogle Scholar
  15. 15.
    Wolff HG (1963) Headache and other head pain. Oxford University Press, New YorkGoogle Scholar
  16. 16.
    Moskowitz MA (1991) The visceral organ brain: implications for the pathophysiology of vascular head pain. Neurology 41: 182–186PubMedCrossRefGoogle Scholar
  17. 17.
    Moskowitz MA, MacFarlane R (1993) Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev 5: 159–177PubMedGoogle Scholar
  18. 18.
    Cutrer FM, Sorensen AG, Weisskoff RM et al (1998) Perfusion-weighted imaging defects during spontaneous migraine aura. Ann Neurol 43: 25–31PubMedCrossRefGoogle Scholar
  19. 19.
    Lashley KS (1941) Patterns of cerebral integration indicated by the scotomas of migraine. Arch Neurol Psychiat 46: 331–339CrossRefGoogle Scholar
  20. 20.
    Milner PM (1958) Note on a possible correspondence between the scotomas of migraine and spreading depression of Ledo. Electroencephalogr Clin Neurophysiol 10: 705PubMedCrossRefGoogle Scholar
  21. 21.
    Andersen AR, Friberg L, Olsen TS, Olesen J (1988) SPECT demonstration of delayed hyperemia following hypoperfusion in classic migraine. Arch Neurol 45: 154–159PubMedCrossRefGoogle Scholar
  22. 22.
    Lauritzen M, Olesen J (1984) Regional cerebral blood flow during migraine attacks by xenon-133 inhalation and emission tomography. Brain 107: 447–461PubMedCrossRefGoogle Scholar
  23. 23.
    Woods RP, Iacoboni M, Mazziotta JC (1994) Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 331: 1689–1692PubMedCrossRefGoogle Scholar
  24. 24.
    Weiller C, May A, Limmroth V et al (1995) Brainstem activation in spontaneous human migraine attacks. Nature Med 7: 658–660Google Scholar
  25. 25.
    May A, Kaube H, Buchel C et al (1998) Experimental cranial pain elicited by capsaicin: a PET study. Pain 74: 61–66PubMedCrossRefGoogle Scholar
  26. 26.
    Cutrer FM, O’Donnell AO, Sanchez del Rio M (2000) Functional neuroimaging: enhanced understanding of migraine pathophysiology. Neurology 55 (Suppl 2): S36–S45PubMedGoogle Scholar
  27. 27.
    Markowitz S, Saito K, Moskowitz MA (1987) Neurogenically mediated leakage of plasma proteins occurs from blood vessels in dura mater but not brain. J Neurosci 7: 4129–4136PubMedGoogle Scholar
  28. 28.
    Buzzi MG, Moskowitz MA (1991) Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia 11: 165–168PubMedCrossRefGoogle Scholar
  29. 29.
    Lassen L, Jacobsen V, Petersen P et al (1998) Human calcitonin gene-related peptide (hCGRP)-induced headache in migraineurs (abstract). Eur J Pharmacol 5 (Suppl 3): S63Google Scholar
  30. 30.
    Goadsby PJ, Edvinsson L (1994) Human in vivo evidence for trigeminovascular activation in cluster headache: neuropeptide changes and effects of acute attack therapies. Brain 17: 424–434Google Scholar
  31. 31.
    Kaube H, Keay KA, Hoskin KL et al (1993) Expression of c-fos-like immunoreactivity in the caudal medulla and upper cervical spinal cord following stimulation of the superior sagittal sinus in the cat. Brain Res 629: 95–102PubMedCrossRefGoogle Scholar
  32. 32.
    Olesen J, Thomsen LL, Iversen H (1994) Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol Sci 15: 149–153PubMedCrossRefGoogle Scholar
  33. 33.
    U.S. Headache Consortium (2000) American Academy of Neurology Headache Guidelines at: Google Scholar
  34. 34.
    Cady RK, Sheftell F, Lipton RB et al (2000) Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther 22: 1035–1048PubMedCrossRefGoogle Scholar
  35. 35.
    O’Quinn S, Davis RL, Gutterman D et al (1999) Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine. Cephalalgia 19: 223–231PubMedCrossRefGoogle Scholar
  36. 36.
    Wood A (2000) Drugs in pregnancy. New Engl J Med 338: 1130–1137Google Scholar
  37. 37.
    Shuhaiber S, Pastuszak A, Schick B et al (1998) Pregnancy outcome following first trimester exposure to sumatriptan. Neurology 51: 581–583PubMedCrossRefGoogle Scholar
  38. 38.
    Scharff L, Marcus DA, Tuck DC (1996) Maintenance of effects in the nonmedical treatment of headaches during pregnancy. Headache 36: 285–290PubMedCrossRefGoogle Scholar
  39. 39.
    Silberstein SD, Massiou H, LeJeunne C et al (2000) Rizatriptan in the treatment of menstrual migraine. Obstetrics Gynecol 96: 237–242CrossRefGoogle Scholar
  40. 40.
    Loder E, Silberstein S (1998) Clinical efficacy of 2.5 and 5 mg zolmitriptan in migraine associated with menses or in patients using non-progestogen oral contraceptives (abstract). Neurology 50 (Suppl 4): A341Google Scholar
  41. 41.
    Salonen R, Saiers J (1999) Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analyses. Cephalalgia 19: 16–19.PubMedCrossRefGoogle Scholar
  42. 42.
    Massiou H, Pitei D, Poole PH, Sikes C (2000) Efficacy of eletriptan for the treatment of migraine in women with menstrually associated migraine, and in women on contraceptives or hormone replacement therapy: meta-analyses of randomized clinical trials (abstract). Cephalalgia 20: 435CrossRefGoogle Scholar
  43. 43.
    Silberstein SD, Armellino JJ, Hoffman HD et al (1999) Treatment of menstruation-associated migraine with the nonprescription combination of acetaminophen, aspirin, and caffeine: results from three randomized, placebo-controlled studies. Clin Ther 21: 475–491PubMedCrossRefGoogle Scholar
  44. 44.
    Szekely B, Merryman S, Croft H et al (1989) Prophylactic effects of naproxen sodium on perimenstrual headache: a double blind placebo controlled study. Cephalalgia 9 (Suppl 10): 452–453Google Scholar
  45. 45.
    Sances G, Martignoni E, Fioroni L et al (1990) Naproxen sodium in menstrual migraine prophylaxis: a double-blind, placebo controlled study. Headache 30: 705–709PubMedCrossRefGoogle Scholar
  46. 46.
    Pradalier A, Vincent D, Beaulieu PH et al (1994) Correlation between oestradiol plasma level and therapeutic effect on menstrual migraine. In: FC Rose (ed): New advances in headache research. Smith-Gordon, London, 129–132Google Scholar
  47. 47.
    Pfaffenrath V (1993) Efficacy and safety of percutaneous estradiol vs. placebo in menstrual migraine (abstract). Cephalalgia 13: 168Google Scholar
  48. 48.
    Herzog AG (1997) Continuous bromocriptine therapy in menstrual migraine. Neurology 48: 101–102PubMedCrossRefGoogle Scholar
  49. 49.
    O’Dea PK, Davis EH (1990) Tamoxifen in the treatment of menstrual migraine. Neurology 40: 1470–1471PubMedCrossRefGoogle Scholar
  50. 50.
    Powles TJ (1986) Prevention of migraineous headaches by tamoxifen. Lancet 2: 1344.PubMedCrossRefGoogle Scholar
  51. 51.
    Silberstein SD, Merriam GR (1993) Sex hormones and headache. J Pain Symptom Management 8: 98–114CrossRefGoogle Scholar

Copyright information

© Springer Basel AG 2002

Authors and Affiliations

  • Elizabeth W. Loder
    • 1
  1. 1.Spaulding Rehabilitation Hospital, Pain Inpatient UnitBostonUSA

Personalised recommendations